LiliumX
www.liliumx.comLiliumX are a recent University of Oxford spinout that drives innovation in bispecific antibody R&D against cancer. We believe that current bispecific antibody R&D is outdated and focused only on limited known biology. We break free of this limitation by using our highly modular high-throughput protein platform to discover novel target combinations to make first-in-class bispecific antibodies with entirely new mechanisms of action. We are backed by mission-driven investors including Y Combinator, Hoxton Ventures, Magnet Ventures, and Acequia Capital. We are disrupting the field of bispecific antibodies and we welcome you to join us in this revolution.
Read moreLiliumX are a recent University of Oxford spinout that drives innovation in bispecific antibody R&D against cancer. We believe that current bispecific antibody R&D is outdated and focused only on limited known biology. We break free of this limitation by using our highly modular high-throughput protein platform to discover novel target combinations to make first-in-class bispecific antibodies with entirely new mechanisms of action. We are backed by mission-driven investors including Y Combinator, Hoxton Ventures, Magnet Ventures, and Acequia Capital. We are disrupting the field of bispecific antibodies and we welcome you to join us in this revolution.
Read moreCountry
City (Headquarters)
London
Industry
Employees
1-10
Founded
2021
Social
Employees statistics
View all employeesPotential Decision Makers
Advisor
Email ****** @****.comPhone (***) ****-****Board Observer
Email ****** @****.comPhone (***) ****-****
Technologies
(12)